Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.
Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.
The combination of high-frequency and low-dose acalabrutinib and rituximab demonstrated a 100% overall response rate in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Patients with previously untreated chronic lymphocytic leukemia derived a better progression-free survival benefit from treatment with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab.
The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.
“I’ve done a lot of work [not only with] clinical trials, but also understanding the disease, the prognostic factors, and the management of adverse effects.”
After implementing disparity and demographic reporting in acute leukemia clinical trials, investigators did not report an increase in diverse trial participants.
CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.
Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.